A meta‑ and bioinformatics analysis of maspin expression levels influencing the prognosis of patients with breast cancer

Shi,Shuai; Zhang,Zhi-Gang; Sang,Yin-Zhou; Sun,Jie; Ma,Hong-Yan

doi:10.3892/ol.2024.14306

A meta‑ and bioinformatics analysis of maspin expression levels influencing the prognosis of patients with breast cancer

Authors:
- Shuai Shi
- Zhi-Gang Zhang
- Yin-Zhou Sang
- Jie Sun
- Hong-Yan Ma
View Affiliations

Affiliations: Department of Pathology, Cangzhou People's Hospital, Cangzhou, Hebei 061000, P.R. China
Published online on: February 23, 2024 https://doi.org/10.3892/ol.2024.14306
Article Number: 173
Copyright: © Shi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Maspin is a serine protease inhibitor that is encoded by the human SERPINB5 gene. As a tumor inhibitor, it can inhibit the growth of tumor cells, increase adhesion between tumor cells and inhibit tumor angiogenesis. In the present study, a meta‑ and bioinformatics analysis was performed through the PubMed and China National Knowledge Infrastructure databases including entries added until up to March 20, 2023. It was found that compared with normal breast tissue, maspin expression was downregulated in breast cancer tissue. Maspin expression was negatively associated with lymph node metastasis. According to Kaplan‑Meier plotter, it was found that lower maspin expression was negatively associated with the overall and distant metastasis‑free survival rate of patients with estrogen receptor‑positive, luminal A and grade 2 breast cancer. High expression of maspin was also positively associated with the relapse‑free survival rate of patients of the luminal A subtype. Low maspin expression was positively associated with the post‑progression and distant metastasis‑free survival rate of the progesterone receptor‑negative subtype. According to the GEPIA database, SERPINB5 mRNA expression was higher in normal than breast cancer tissues and negatively correlated with the TNM stage. High expression of maspin was also positively associated with the overall survival rate. In the UALCAN database, it was found that the mRNA and promoter methylation levels of SERPINB5 were higher in normal than in breast cancer tissues. These findings suggest that the expression of maspin may serve as a potential marker to indicate the occurrence, subsequent progression and even prognosis of breast cancer.

View Figures

View References

1	Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveu M, Sheng S, Rafidi K, Seftor E and Sager R: Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science. 263:526–529. 1994. View Article : Google Scholar : PubMed/NCBI
2	Bailey CM, Khalkhali-Ellis Z, Seftor EA and Hendrix MJC: Biological functions of maspin. J Cell Physiol. 209:617–624. 2006. View Article : Google Scholar : PubMed/NCBI
3	Sheng S, Carey J, Seftor EA, Dias L, Hendrix MJ and Sager R: Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci USA. 93:11669–11674. 1996. View Article : Google Scholar : PubMed/NCBI
4	Zhang W and Zhang M: Tissue microarray analysis of maspin expression and its reverse correlation with mutant p53 in various tumors. Int J Oncol. 20:1145–1150. 2002.PubMed/NCBI
5	Loo JA, Yan W, Ramachandran P and Wong DT: Comparative human salivary and plasma proteomes. J Dent Res. 89:1016–1023. 2010. View Article : Google Scholar : PubMed/NCBI
6	Sopel M, Surowiak P and Berdowska I: Nuclear maspin expression as a good prognostic factor in human epithelial ovarian carcinoma. Folia Morphol (Warsz). 69:204–212. 2010.PubMed/NCBI
7	Yin S, Lockett J, Meng Y, Biliran H Jr, Blouse GE, Li X, Reddy N, Zhao Z, Lin X, Anagli J, et al: Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system. Cancer Res. 66:4173–4181. 2006. View Article : Google Scholar : PubMed/NCBI
8	Endsley MP, Hu Y, Deng Y, He X, Warejcka DJ, Twining SS, Gonias SL and Zhang M: Maspin, the molecular bridge between the plasminogen activator system and beta1 integrin that facilitates cell adhesion. J Biol Chem. 286:24599–24607. 2011. View Article : Google Scholar : PubMed/NCBI
9	Odero-Marah VA, Khalkhali-Ellis Z, Chunthapong J, Amir S, Seftor RE, Seftor EA and Hendrix MJ: Maspin regulates different signaling pathways for motility and adhesion in aggressive breast cancer cells. Cancer Biol Ther. 2:398–403. 2003. View Article : Google Scholar : PubMed/NCBI
10	Biliran H Jr and Sheng S: Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Cancer Res. 61:8676–8682. 2001.PubMed/NCBI
11	Alvarez Secord A, Darcy KM, Hutson A, Huang Z, Lee PS, Jewell EL, Havrilesky LJ, Markman M, Muggia F and Murphy SK: The regulation of MASPIN expression in epithelial ovarian cancer: Association with p53 status, and MASPIN promoter methylation: A gynecologic oncology group study. Gynecol Oncol. 123:314–319. 2011. View Article : Google Scholar : PubMed/NCBI
12	Moher D, Liberati A, Tetzlaff J, Altman DG, Antes G, Atkins D, Barbour V, Barrowman N, Berlin JA, Clark J, et al: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Rev Esp Nutr Hum Diet. 18:172–181. 2014. View Article : Google Scholar
13	Luchini C, Stubbs B, Solmi M and Veronese N: Assessing the quality of studies in meta-analyses: Advantages and limitations of the Newcastle Ottawa Scale. World J Meta Anal. 5:80–84. 2017. View Article : Google Scholar
14	Liu W, Zhang XH, Zhang ZG, Wang XL, et al: The relationship between the maspin, BCSG1 and c-erbB-2 expression and the prognosis of breast cancer. Chin J Clin Oncol. 32:431–434. 2005.
15	Liu W, Zhang XH, Zhang ZG, Wang XL, et al: The significance of expression of maspin in breast cancer and lesions in the neighborhood of cancer. Chin J Clin Oncol. 31:1272–1276. 2004.
16	Hu W and Xing LQ: Significance of maspin protein expression in breast cancer. Chin J Misdiagnostics. 6:4526–4528. 2006.
17	Zhang W, Wang RY, Li J and Zhang XY: Expression and clinical significance of Maspin and MMP-2 in breast infiltrative ductal carcinoma. Chin J Surg Oncol. 6:225–229. 2014.
18	Liu JC, Jiang ZM, Li Xin and Liu XZ: Expressions of maspin and p53 in breast cancer and its clinical signifi cance. Chin J Bases Clin Gen Surg. 20:547–550. 2013.
19	Sun G, Shi CQ, Zhang M and Qi Y: Expression and clinical significance of maspin and p53 in breast cancer. J Clin Exp Med. 13:328–330. 2014.
20	Yang WP, Wei CY, Zhou HJ, Ding ZL and Li H: Expression of maspin in 65 cases with breast cancer and its significance. J Oncol. 16:163–167. 2010.
21	Ding YF, Feng YZ, Ping JL, Wang XH and Li F: The clinical significance of maspin expression in breast cancer. Suzhou Univ J Med Sci. 27:396–398. 2006.
22	Cao GF, Zhang CH and You QH: Different expressions of maspin in human mammary cancer of different ER expressions. Med J Commun. 20:23–24. 2006.
23	Zhu XQ and Gong DS: Maspin expression in breast cancer and its relationship with microvessel density. J Surg Concepts Pract. 12:353–356. 2007.
24	Chen SP, Che AW, Tan XD, Li JL and Kong JG: Expression and clinicopathological significance of Maspin and Bmi-1 in breast cancer. Hebei Med J. 37:2774–2776. 2015.
25	Pei XH, Wang F and Yu Z: Expression and significance of Maspin and uPA in breast cancer. 51:71–72. 2011.
26	Fang F, Li TC and Wu P: Analysis of maspin protein expression and maspin gene promoter methylation in breast cancer tissue. Carcinog Teratog Mutagen. 21:42009.
27	Zhang QY, Chen XD, Li JW, Yu HF, Liang QL, Huang SC and Zhang Z: Expression of vascular endothelial growth factor and Maspin in breast carcinoma and its clinical significance. Prog Mod Biomed. 12:493–496. 2012.
28	Zhang W, Qiao SP, Shang PZ, Liu B, Li W and Nan RL: Clinicopathologic study on expression sleX and maspin in invasive ductal carcinoma tissue of breast. J Hebei North Univ. 38:1–8. 2022.
29	Liu XZ, Zhou SF, Cai FL, Wu YY and Jin LF: Expression and clinical significance of maspin and uPA in breast cancer. J Mod Oncol. 17:2139–2142. 2009.
30	Wang LX, Zhao PR, Wang B, Fan QX, Wang RL and Zhang GM: The different expression of maspin in human mammary cancer of different CerbB-2 expression. J Basic Clin Oncol. 18:85–86. 2005.
31	Wakahara M, Sakabe T, Kubouchi Y, Hosoya K, Hirooka Y, Yurugi Y, Nosaka K, Shiomi T, Nakamura H and Umekita Y: Subcellular localization of maspin correlates with histone deacetylase 1 expression in human breast cancer. Anticancer Res. 37:50712017.PubMed/NCBI
32	Tuncel F, Bozkurt F and Berkesoglu M: The value of maspin and PD-L1 expression and peritumoral lymphocytic infiltration in breast tumors. Bratisl Lek Listy. 121:894–900. 2020.PubMed/NCBI
33	Feng Y, Zhu J, Shi JP, Wang HL and Zhang Y: Expression and significances of inhibitors of DNA binding-1, maspin in invasive ductal cancer with breast infiltrations. J Lanzhou Univ. 34:42008.
34	Helal DS and El-Guindy DM: Maspin expression and subcellular localization in invasive ductal carcinoma of the breast: Prognostic significance and relation to microvessel density. J Egypt Natl Canc Inst. 29:177–183. 2017. View Article : Google Scholar : PubMed/NCBI
35	Lee MJ, Suh CH and Li ZH: Clinicopathological significance of maspin expression in breast cancer. J Korean Med Sci. 21:309–14. 2006. View Article : Google Scholar : PubMed/NCBI
36	Kim DH, Yoon DS, Dooley WC, Nam ES, Ryu JW, Jung KC, Park HR, Sohn JH, Shin HS and Park YE: Association of maspin expression with the high histological grade and lymphocyte-rich stroma in early-stage breast cancer. Histopathology. 42:37–42. 2003. View Article : Google Scholar : PubMed/NCBI
37	Umekita Y and Yoshida H: Expression of maspin is up-regulated during the progression of mammary ductal carcinoma. Histopathology. 42:541–545. 2003. View Article : Google Scholar : PubMed/NCBI
38	Joensuu KM, Leidenius M, Andersson LC and Heikkilä PS: High expression of maspin is associated with early tumor relapse in breast cancer. Hum Pathol. 40:1143–1151. 2009. View Article : Google Scholar : PubMed/NCBI
39	Prasad CP, Rath G, Mathur S, Bhatnagar D and Ralhan R: Expression analysis of maspin in invasive ductal carcinoma of breast and modulation of its expression by curcumin in breast cancer cell lines. Chem Biol Interact. 183:455–461. 2010. View Article : Google Scholar : PubMed/NCBI
40	Oliveira AM, Ross JS and Fletcher JA: Tumor suppressor genes in breast cancer: The gatekeepers and the caretakers. Am J Clin Pathol. 124 (Suppl):S16–S28. 2005.PubMed/NCBI
41	Zhang B, Liu K and Chen JY: Combination of 5-Aza-CdR and trichostatin A on cell proliferation and maspin gene expression in breast cancer cell line MDA-MB-435S. Chin J Cancer Prev Treat. 15:725–728. 2008.
42	Liu HY, Cheng G and Li ZP: The epigenetics mechanism of maspin silencing in glioma. Yiayao Qianyan. 27:103–105. 2020.
43	Man XB, Tang L, Qiu XH, Yang LQ, Cao HF, Wu MC and Wang HY: Expression of cytochrome P4502E1 gene in hepatocellular carcinoma. World J Gastroenterol. 10:1565–1568. 2004. View Article : Google Scholar : PubMed/NCBI
44	Khalkhali-Ellis Z, Zhang M and Hendrix MJC: Maspin and cathepsin d partnership in regulating mammary gland development and breast cancer. Breast Cancer: Causes. Diagnosis and Treatment. Romero MR: Nova Science Publishers, Inc.; pp. 161–176. 2011
45	Lim S, Hung AC and Porter AG: Focused PCR screen reveals p53 dependence of nitric oxide-induced apoptosis and up-regulation of maspin and plasminogen activator inhibitor-1 in tumor cells. Mol Cancer Res. 7:55–66. 2009. View Article : Google Scholar : PubMed/NCBI
46	Jiang WG, Hiscox S, Horrobin DF, Bryce RP and Mansel RE: Gamma linolenic acid regulates expression of maspin and the motility of cancer cells. Biochem Biophys Res Commun. 237:639–644. 1997. View Article : Google Scholar : PubMed/NCBI
47	Yin S, Li X, Meng Y, Finley RL Jr, Sakr W, Yang H, Reddy N and Sheng S: Tumor-suppressive maspin regulates cell response to oxidative stress by direct interaction with glutathione S-transferase. J Biol Chem. 280:34985–3496. 2005. View Article : Google Scholar : PubMed/NCBI
48	Shui HH, Luo L, Liang SZ, ZHuang L and Li W: The expression of Maspin protein in oral squamous cell carcinoma and its significance. Hua Xi Kou Qiang Yi Xue Za Zhi. 26:604–606. 6102008.(In Chinese). PubMed/NCBI
49	Caro AA and Cederbaum AI: Role of phospholipase A2 activation and calcium in CYP2E1-dependent toxicity in HepG2 cells. J Biol Chem. 278:33866–33877. 2003. View Article : Google Scholar : PubMed/NCBI
50	Zheng HC and Gong BC: The roles of maspin expression in gastric cancer: A meta- and bioinformatics analysis. Oncotarget. 8:66476–66490. 2017. View Article : Google Scholar : PubMed/NCBI
51	Liang XF, Cui ZY, Peng BY, et al: Maspin and p73 in endometrial cancer tissue Expression level and its correlation analysis. World's Latest Med Inf Dig. 21:390–391. 2021.
52	Wang Y, Sheng S, Zhang J, Dzinic S, Li S, Fang F, Wu N, Zheng Q and Yang Y: Elevated maspin expression is associated with better overall survival in esophageal squamous cell carcinoma (ESCC). PLoS One. 8:e635812013. View Article : Google Scholar : PubMed/NCBI
53	Yoshizawa K, Nozaki S, Okamune A, Kitahara H, Ohara T, Kato K, Kawashiri S and Yamamoto E: Loss of maspin is a negative prognostic factor for invasion and metastasis in oral squamous cell carcinoma. J Oral Pathol Med. 38:535–539. 2009. View Article : Google Scholar : PubMed/NCBI
54	Lu M, Li J, Huang Z, Du Y, Jin S and Wang J: Aberrant maspin mRNA expression is associated with clinical outcome in patients with pulmonary adenocarcinoma. Med Sci Monit. 22:134–139. 2016. View Article : Google Scholar : PubMed/NCBI